Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
PTPI - Petros Pharmaceuticals, Inc.
Market Cap 8.26M P/E - EPS this Y 66.50% Ern Qtrly Grth -
Income -20.64M Forward P/E - EPS next Y 48.80% 50D Avg Chg 40.00%
Sales 4.12M PEG - EPS past 5Y - 200D Avg Chg 29.00%
Dividend N/A Price/Book 0.53 EPS next 5Y - 52W High Chg -59.00%
Recommedations 2.00 Quick Ratio 0.93 Shares Outstanding 9.61M 52W Low Chg 326.00%
Insider Own 8.44% ROA -30.61% Shares Float 8.94M Beta 2.30
Inst Own 2.16% ROE -63.77% Shares Shorted/Prior 235.11K/260.70K Price 3.91
Gross Margin 70.21% Profit Margin -171.24% Avg. Volume 413,508 Target Price 1.00
Oper. Margin -160.46% Earnings Date - Volume 69,348 Change -1.01%
Healthcare | Drug Manufacturers - Specialty & Generic | United States
About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Petros Pharmaceuticals, Inc. News
12/19/24 Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
12/17/24 Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
11/16/24 Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
09/11/24 Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
09/03/24 Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/17/24 Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
07/29/24 Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
07/16/24 Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
05/29/24 Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
05/21/24 Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
05/14/24 Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
05/14/24 Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
04/23/24 Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
04/16/24 Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
04/02/24 Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
03/19/24 Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
02/14/24 Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
09:15 AM Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
01/17/24 Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch